SRC transcriptional activation in a subset of human colon cancer cell lines  by Dehm, Scott et al.
SRC transcriptional activation in a subset of human colon cancer
cell lines
Scott Dehma, Mary-Anne Sengerb, Keith Bonhamb;*
aDepartment of Biochemistry, University of Saskatchewan, Saskatoon, Sask., Canada S7N 5E5
bCancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, and the Division of Oncology, University of Saskatchewan,
Saskatoon, Sask., Canada S7N 4H4
Received 29 November 2000; accepted 30 November 2000
First published online 8 December 2000
Edited by Veli-Pekka Lehto
Abstract Human SRC encodes the non-receptor tyrosine
kinase pp60cÿSrc, which is activated in many human colon cancer
cell lines (HCCLs) and tumors. We found that both c-Src protein
and mRNA levels were elevated in a subset of HCCLs. Increased
c-Src mRNA and protein levels correlated strongly with
increased c-Src kinase activity. Nuclear run-on analysis and c-
Src mRNA half-life determination demonstrated increased
mRNA levels were due to increased transcription of the SRC
gene. We also observed decreased c-Src mRNA stability in cell
lines that displayed SRC transcriptional activation. Our findings
provide the first evidence that SRC transcriptional activation is
an important determinant of c-Src expression and activity in
HCCLs. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Colorectal cancer (CRC) is the fourth most common malig-
nancy a¡ecting the Western population, and the second lead-
ing cause of deaths due to cancer [1]. The genetic events lead-
ing to malignant disease have been well documented, allowing
stepwise models of colonic tumorigenesis to be elucidated
[2,3]. In addition to these genetic anomalies, activation of
the non-receptor tyrosine kinase pp60cÿSrc has been a consis-
tent early ¢nding in CRC [4^10]. The recent report of an
activating SRC mutation in a small subset (12%) of highly
advanced colon tumors has veri¢ed an important role for c-
Src in progression of CRC [11]. However, in the vast majority
of CRC, c-Src is activated through non-mutagenic means. In
many studies, increased c-Src kinase activity can be explained
by a concomitant overexpression of pp60cÿSrc, suggesting
overexpression of pp60cÿSrc could play an important role in
colorectal tumorigenesis [4,7,8,12^14]. Indeed, overexpression
of normal c-Src is able to cause transformation of mouse
¢broblasts [15], with synergistic levels of transformation
achieved upon co-overexpression with epidermal growth fac-
tor receptor (EGFR) [16]. In addition, antisense-mediated
down-regulation of c-Src expression in the HT29 colon ad-
enocarcinoma cell line results in severely diminished tumor-
igenicity and reduced vascular endothelial growth factor ex-
pression [17,18]. Activation and/or overexpression of c-Src has
also been observed in other human tumors, notably those of
the breast [19,20], lung [21,22], pancreas [23,24] and liver [25].
However, the precise mechanism by which c-Src activation
occurs in colon and other cancers has not been determined.
Here we report a strong correlation between elevated
pp60cÿSrc kinase activity, elevated pp60cÿSrc levels and in-
creased c-Src mRNA levels in human colon cancer cell lines
(HCCLs). Increased c-Src mRNA resulted from transcription-
al activation of the SRC gene. Our ¢ndings therefore impli-
cate SRC transcriptional activation, a previously unrecog-
nized form of c-Src regulation, as an important determinant
of c-Src expression and activity in HCCLs, as well as a po-
tentially important event in colon tumorigenesis.
2. Materials and methods
2.1. Cell culture
The HT29, WiDr, SW480, SW620, and LS174-T, HCCLs were
obtained from the American Type Culture Collection (ATCC) and
grown in Dulbecco’s modi¢ed Eagle’s medium media and 10% fetal
calf serum (Gibco). COLO 201, COLO 205, COLO 320, DLD-1 and
HCT-15 cell lines were also from ATCC and were grown in RPMI
1640 media with 10% fetal calf serum. The HCT-116 cell line (ATCC)
was grown in McCoy’s 5A media with 10% fetal calf serum. The
KM12C cell line was a gift of Dr. Fidler (MD Anderson Cancer
Center). All cells were maintained at 37‡C and 5% CO2.
2.2. Plasmid constructs
c-Src cDNA clones have been described previously [26]. HHC189
containing a 1.1 kb insert of L-actin and pGD-P-25A containing a
1.5 kb insert of glucose-6-phosphate dehydrogenase were obtained
from the ATCC. pMI containing exons 2 and 3 of the human c-
Myc gene was a gift of Dr. Zheng (Department of Pathology, Uni-
versity of Saskatchewan). pRibo containing a 5.8 kb insert of 18S
ribosomal RNA cDNA was a gift of Dr. W. Roesler (Department
of Biochemistry, University of Saskatchewan).
2.3. mRNA extraction and Northern blot analysis
For mRNA half-life studies, actinomycin D was added to semi-
con£uent cells to a ¢nal concentration of 5 Wg/ml. Following actino-
mycin D addition, cells were harvested at various time points and
total cellular RNA was isolated using the method of Chomcyznski
and Sacchi [27]. For other Northern blotting experiments, cells were
grown until they were semi-con£uent, then harvested; RNA was iso-
lated using the same methodology. Equal amounts (15 Wg per lane) of
total cellular RNA were fractionated in 1% denaturing formaldehyde^
agarose gels. RNA was transferred to Gene Screen nylon membranes
(DuPont) by capillary elution, UV cross-linked, and then hybridized
with cDNA probes speci¢c for c-Src, c-Myc or L-actin labeled with
[K-32P]dCTP using an oligolabeling kit (Pharmacia). Autoradiography
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was performed at 380‡C using an intensi¢er screen (Kodak). For
actinomycin D mRNA half-life studies, 1 week exposures to ¢lm
were necessary to generate a signal for c-Src expression in SW480
and SW620, compared with overnight exposures for HT29, COLO
201 and COLO 205.
2.4. Immunoblot analysis
Cells from semi-con£uent 10 cm plates were lyzed directly in a
loading bu¡er containing 65 mM Tris^HCl, (pH 7.0), 2% (w/v) so-
dium dodecyl sulfate (SDS), 5% L-mercaptoethanol, 10% glycerol and
0.05% (w/v) bromophenol blue at the same time as plates used for
Northern blot analysis. Following protein concentration determina-
tion using a Lowry kit (Sigma), 30 Wg of total cellular protein was
resolved on a 10% SDS^polyacrylamide gel. Gel transfer to nitrocel-
lulose and membrane blocking were performed using standard proce-
dures. The blot was incubated ¢rst with the pp60cÿSrc speci¢c mono-
clonal antibody, mAb 327 (a gift from Dr. J. Brugge) at 1.0 Wg/ml,
washed and probed with an anti-mouse IgG horseradish peroxidase
conjugate (Santa Cruz) diluted 1:2000. Membranes were then incu-
bated in chemiluminescence reagents (Dupont) and exposed to Kodak
X-OMAT Blue XB-1 ¢lm for detection.
2.5. Cell lysate preparation, immunoprecipitations and in vitro
c-Src kinase assays
Cells were lyzed in ice-cold, modi¢ed RIPA bu¡er. Immunoprecip-
itation and in vitro c-Src kinase assays were subsequently performed
as described [28]. Brie£y, lysate containing 500 Wg of total cellular
protein was incubated with excess mAb 327 for 1 h at 4‡C. Immune
complexes were collected by the addition of 30 Wl of a 30% protein G^
Sepharose slurry, incubation for 30 min at 4‡C, and centrifugation at
10 000Ug for 1 min at 4‡C. Immunoprecipitate pellets were re-sus-
pended in 40 Wl of a kinase reaction bu¡er containing 0.25 M N-2-
hydroxyethylpiperazine-NP-2-ethanesulfonic acid (HEPES), pH 7.8,
25 mM MgCl2, 0.75 M NaCl, 1 WCi [Q-32P]ATP, 10 WM ATP, 300
WM Src optimal peptide (AEEEIYGEFEAKKKK) [29], 200 WM so-
dium orthovanadate, and 4 mg/ml p-nitrophenol phosphate for 15 min
at 30‡C. Reactions were terminated by the addition of 25 Wl of 50%
(v/v) acetic acid. Aliquots from each reaction were spotted onto p81
phosphocellulose squares, which were subsequently washed three
times in 0.5% (v/v) phosphoric acid, dried and counted in a scintilla-
tion counter; two independent experiments were performed.
2.6. Nuclei puri¢cation and nuclear run-on analysis
Approximately 3U108 cells were harvested and re-suspended in
nuclear isolation bu¡er (60 mM KCl, 15 mM NaCl, 5 mM MgCl2,
0.1 mM EDTA, 15 mM Tris^HCl, pH 7.4, 0.5 mM dithiothreitol
(DTT), 0.1 mM phenylmethylsulfonyl £uoride and 300 mM sucrose).
Cells were gently lyzed by addition of Nonidet-P-40 to a ¢nal con-
centration of 0.5%. The crude preparation of nuclei was then layered
onto the same bu¡er containing 1.7 M sucrose. Nuclei were pelleted
through the sucrose cushion, re-suspended in nuclear storage bu¡er
(50 mM Tris^HCl, pH 8.3, 40% glycerol, 0.1 mM EDTA and 0.1 mM
DTT) and snap-frozen. Nuclear run-ons were then performed essen-
tially as described [30] with a few minor modi¢cations. Brie£y, nuclei
were thawed and an equal volume of 2U reaction bu¡er (10 mM
Tris^HCl, pH 7.5, 5 mM MgCl2, 0.3 M KCl, 5 mM DTT, 1 mM
each of ATP, GTP and UTP) and 50 WCi of [K-32P]dCTP (3000 Ci/
mmol) were added. Following incubation at room temperature for
30 min, 20 U of RNase-free DNase was added, then incubation was
continued for a further 5 min. Labeled RNA was isolated as described
[27]. The labeled RNA (usually 5U106 cpm/reaction) was then hy-
bridized to a series of DNA probes (10 Wg/sample) immobilized on
Zeta Probe nylon membranes (Bio-Rad) using a slot blot apparatus.
Hybridization conditions were the same as described for Northern
blots.
3. Results
3.1. Overexpression of c-Src mRNA results in increased
c-Src protein and kinase activity in HCCLs
We have examined both the level and speci¢c kinase activity
of pp60cÿSrc in a number of HCCLs. In agreement with re-
ports from other groups [7,8], increased c-Src kinase activity
in HCCLs could be explained by a concomitant overexpres-
sion of c-Src protein (compare Fig. 1B and C). To determine
the mechanism of pp60cÿSrc overexpression, we also examined
c-Src mRNA levels in the same HCCLs (Fig. 1A). We found
those cell lines that constitutively overexpressed pp60cÿSrc
(HT29, COLO 201, COLO 205, WiDr and LS174-T), and
hence had increased c-Src kinase activity, also expressed high-
er levels of c-Src mRNA than cell lines that have lower levels
of pp60cÿSrc and lower c-Src kinase activity. The only cell line
that did not follow this consistent trend was the COLO 320
cell line. These cells displayed intermediate steady state c-Src
mRNA levels, low pp60cÿSrc levels and low c-Src kinase ac-
tivity. This particular cell line also displayed unusually high
levels of c-Myc mRNA which resulted from a massive ampli-
¢cation of the C-MYC gene in the form of double minute
chromosomes [31].
3.2. c-Src overexpression results from transcriptional activation
of the SRC gene
To determine if the observed increase in c-Src mRNA and
protein levels resulted from increased transcription of the
SRC gene, we performed nuclear run-on analysis using repre-
sentative cell lines as described in Section 2 (Fig. 2). We were
able to reproducibly detect a higher signal for c-Src in over-
Fig. 1. c-Src mRNA, protein expression levels and kinase activity in
various HCCLs. (A) Northern blot of total RNA from semi-con£u-
ent cells sequentially probed speci¢cally for c-Src, c-Myc and L-actin
as described in Section 2. (B) Western blot of total cellular proteins
from the same cell lines harvested at the same time as in (A), using
a speci¢c anti-pp60cÿSrc monoclonal antibody. (C) In vitro kinase
assay of c-Src immunoprecipitated from cell lysates prepared at the
same time as in (A). c-Src kinase activity is expressed as pmol of
PO4 incorporated into the synthetic Src optimal peptide AEEEIY-
GEFEAKKKK [29] per minute per mg of total cellular protein.
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expressing cell lines, such as COLO 205 and HT29, when
compared to low expressing cell lines such as SW620. We
were consistently unable to detect any signal for SRC tran-
scription in low expressing cell lines, such as SW620, despite
transcription rates of a number of control genes being similar
to other cell lines, such as HT29 and COLO 205. These results
suggested that the SRC gene was transcribed at a relatively
higher rate in the c-Src overexpressing cell lines compared to
the low expressing cell lines.
However, the steady state levels of mRNA detected in the
Northern blots could also be in£uenced by di¡erential mRNA
stability. To corroborate nuclear run-on results, we examined
c-Src mRNA half-life in these HCCLs (Fig. 3). Following
inhibition of cellular transcription by actinomycin D, total
RNA was isolated at various time points and analyzed by
Northern blotting. In all cases, we found that the ubiquitously
expressed c-Myc transcripts were rapidly degraded. In con-
trast, we found that levels of L-actin mRNA remained con-
stant throughout the course of the experiment. However,
when we examined the stability of c-Src mRNA we found
some interesting di¡erences. In cells that expressed low levels
of c-Src (SW480, SW620), the c-Src transcripts were stable
over the time course of the study. Conversely, in high c-Src
expressing cell lines (HT29, COLO 201, COLO 205), the c-Src
transcripts were rapidly degraded with an estimated half-life
of less than 2 h. We have con¢rmed this pattern of di¡erential
c-Src mRNA stability in other high and low expressing cell
lines including WiDr and DLD-1 (S. Dehm and K. Bonham,
unpublished data). Taken together, the data from mRNA
stability studies and nuclear run-on experiments demonstrate
that the mechanism of c-Src overexpression in this subset of
HCCLs is at the level of transcription.
4. Discussion
The mechanism of c-Src activation in colon tumors and cell
lines has remained elusive despite the evidence supporting an
important role for c-Src in CRC. Our results showed in-
creased c-Src kinase activity in a subset of HCCLs correlated
with a concomitant increase in c-Src protein levels. Further-
more, those cell lines that exhibited elevated pp60cÿSrc levels
also had elevated c-Src mRNA levels, compared with cell lines
that had lower c-Src protein and kinase activity. Thus, a
strong trend existed between elevated c-Src kinase activity,
Fig. 2. Transcriptional activation in two high c-Src expressing cell
lines versus a low c-Src expressing cell line. Nuclei were prepared
from HT29, COLO 205 and SW620 cell lines and run-ons per-
formed as described in Section 2. 32P-labeled RNA from these nu-
clei was then hybridized to a nylon membrane containing 10 Wg
slot-blots of denatured c-Src, pBS (pBluescript), L-actin, c-Myc,
pGD (glucose-6-phosphate dehydrogenase), and pRibo (18S riboso-
mal RNA cDNA) as indicated.
Fig. 3. Di¡erential stability of c-Src mRNA in high c-Src expressing (HT29, COLO 201, COLO 205) versus low c-Src expressing (SW480,
SW620) colon cancer cell lines. Total RNA was isolated from ¢ve colon cancer cell lines at various times following exposure to 5 Wg/ml actino-
mycin D. Total RNA was blotted and hybridized sequentially with probes speci¢c for c-Src, c-Myc and L-Actin. Much longer exposures to
¢lm were necessary to generate a signal for c-Src mRNA in SW480 and SW620 compared with HT29, COLO 201, and COLO 205. Lane num-
bering refers to hours after actinomycin D addition that cells were harvested.
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increased pp60cÿSrc levels, and increased c-Src mRNA levels.
Further analysis showed increased c-Src mRNA in these cell
lines was the result of transcriptional activation of the SRC
gene. SRC transcriptional activation is therefore an impor-
tant, yet previously unrecognized event that contributes to
increased c-Src expression and kinase activity in a subset of
HCCLs.
An interesting but unexpected ¢nding resulting from this
study was di¡erential c-Src mRNA stability. Those cell lines
that displayed increased c-Src mRNA, protein and kinase
activity had decreased c-Src mRNA stability when compared
with cell lines that had lower levels of c-Src mRNA. This
¢nding suggests an even higher level of SRC transcription
than previously anticipated to account for steady state c-Src
mRNA levels observed during Northern blot analysis. While
the mechanism of this di¡erential stability is not yet known,
we have recently identi¢ed evolutionarily conserved elements
in the 3P untranslated region of the c-Src transcript that could
function as stabilizing elements (S. Dehm and K. Bonham,
unpublished data). Destabilization of c-Src mRNA in cell
lines where SRC is transcriptionally activated could represent
a negative feedback form of regulation. If so, this would par-
allel ¢ndings where elevated pp60cÿSrc kinase activity results in
decreased c-Src protein stability [32,33], suggesting there exist
multiple layers of feedback regulation to prevent inappropri-
ate pp60cÿSrc overexpression.
Two promoters, termed SRC1A and SRC1K, control tran-
scription of the SRC gene [26,34,35]. The SRC1A promoter
has all the hallmarks of a housekeeping promoter; it is GC
rich, lacks TATA or CAAT regulatory motifs, and is regu-
lated by the Sp-family of transcription factors as well as a
novel factor termed SPy [26,34]. Conversely, the SRC1K pro-
moter shows a more tissue-restricted pattern of expression and
is regulated by the liver-enriched transcription factor hepato-
cyte nuclear factor-1K [35]. We have analyzed the relative
levels of transcripts arising from these two promoters, and
we have shown that they are used to di¡erent degrees in
many of the HCCLs described here [35]. We are currently
investigating the mechanisms determining di¡erential pro-
moter usage and transcriptional activation of the SRC gene.
In addition to transcriptional activation of the SRC gene,
we have also noted an inverse correlation between SRC tran-
scriptional activation and documented KRAS gene status in
these same HCCLs. The SW480, SW620, HCT-116, HCT-15
and DLD-1 HCCLs have low levels of c-Src mRNA, low to
intermediate levels of pp60cÿSrc, low c-Src kinase activity and
have an activated mutant KRAS allele [36]. Conversely, the
HT29, WiDr, COLO 201 and COLO 205 cell lines display
SRC transcriptional activation and have wild-type KRAS
[36]. This is a particularly striking observation since both c-
Src activation and KRAS mutation are common events in
colon cancer [37,38]. Further investigation is necessary to de-
termine whether these two events may be mutually exclusive
in CRC.
In conclusion, we have demonstrated that SRC transcrip-
tional activation in a subset of HCCLs resulted in increased c-
Src expression and kinase activity. There are also reports that
have suggested that c-Src overexpression and/or activation
could play an important role in other cancers. For example,
a c-Src speci¢c antisense strategy has been employed in the
SKOv-3 ovarian cancer cell line resulting in diminished an-
chorage-independent growth and tumor forming ability in a
xenograft nude mouse model [39]. Similarly, antisense-medi-
ated down-regulation of c-Src expression in NIH3T3 cells en-
gineered to overexpress the EGFR or an EGFR-HER-2 chi-
mera resulted in the reversal of the transformed phenotype of
these cells [40]. Increased c-Src expression and/or kinase ac-
tivity has also been reported in other cancers such as breast
[19,20], lung [21,22], pancreas [23,24] and liver [25]. Since the
exact mechanism of c-Src activation has not been identi¢ed in
these other cancers, it is possible that SRC transcriptional
activation is an important determinant of c-Src expression
and activity in non-colon cancers as well.
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